ELMOD2: proposed roles in regulating mitochondrial fusion and cell cycle
Project Number5F31CA236493-03
Contact PI/Project LeaderTURN, RACHEL ELIZABETH
Awardee OrganizationEMORY UNIVERSITY
Description
Abstract Text
PROJECT SUMMARY
Cancers, though heterogeneous in pathology, are a product of unchecked cell growth caused by perturbation
to essential cellular processes, notably energy metabolism, DNA replication, or the cell cycle. Misregulation of
these pathways can cause severe phenotypes that, together, can lead to oncogenesis: increased DNA content,
multinucleation, supernumerary centrosomes, and increased dependence upon glycolysis as the cellular source
of ATP (resulting in changes to mitochondrial morphology, gene expression, and functions). Even though these
cancer hallmarks have been intensively studied, the mechanism by which lesions to these pathways promote
oncogenesis remains unclear in most cases.
My lab studies ARF family GTPases and the mechanisms that they employ to regulate a wide variety of
essential cellular activities that, when perturbed, can lead to severe pathologies. I used CRISPR technologies to
generate cell lines lacking expression of ELMOD2, a regulator of several members of the ARF family. I
discovered that ELMOD2-/- lines have fragmented mitochondria, and they also have increases in mitotic indices,
supernumerary centrosomes, increased DNA content, multinucleation, and multiciliation, consistent with a defect
in the cell cycle. Thus, I hypothesize that ELMOD2 both acts from inside mitochondria to mediate effects of the
ARL2 GTPase on mitochondrial fusion as well as regulates cytokinesis from a distinct cellular compartment. To
tease apart the underlying mechanisms that drive these functions, I will use mammalian cell culture to visualize
and assess mitochondrial activity and cell cycle. In Aim 1, I will determine if ELMOD2 acts downstream of ARL2
to regulate mitochondrial fusion, independent of its roles in cell cycle. I will perform a series of rescue experiments
to characterize ELMOD2’s role in this pathway and its relationship to other players in mitochondrial fusion. In
Aim 2, I will define ELMOD2’s functions in cell cycle. I will begin by teasing apart the stage of cell cycle that is
perturbed by loss of ELMOD2. I will determine which ARF family GTPase(s) ELMOD2 works with to alter
mitochondrial dynamics and cell cycle. Overall, this project will contribute to our fundamental understanding of
mitochondrial fusion and cell cycle, two critical pathways whose regulation is incompletely understood. This will
broaden our understanding of regulatory GTPase biology and how GAPs may facilitate multi-pathway
communication. Such findings will pave the way for the future design of novel therapeutics that will precisely
target the source of cancer and other pathologies.
Public Health Relevance Statement
PROJECT NARRATIVE
Though cancers are a collection of many different diseases, they often share a number of hallmark defects in
fundamental cellular processes, including sources of energy production, entry into cell cycling/replication, and
cell division. Consequently, there is a need to understand how disruption of specific cellular mechanics can
cause cancer to arise. The goal of this proposal is to investigate the functions of ELMOD2, a novel regulator of
both cell cycle (the process by which cells grow, replicate, and divide) and mitochondria (a key part of cells that
is essential for energy production), and to determine how ELMOD2 may facilitate communication between these
two systems.
No Sub Projects information available for 5F31CA236493-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5F31CA236493-03
Patents
No Patents information available for 5F31CA236493-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5F31CA236493-03
Clinical Studies
No Clinical Studies information available for 5F31CA236493-03
News and More
Related News Releases
No news release information available for 5F31CA236493-03
History
No Historical information available for 5F31CA236493-03
Similar Projects
No Similar Projects information available for 5F31CA236493-03